ALL Survival Rates Just Got a Boost

Big news for anyone following leukemia treatments: patients with relapsed or refractory ALL who got blinatumomab (BLI) and inotuzumab ozogamicin (INO) before stem cell transplants had way better survival rates than those who got standard chemo. The BLI/INO group saw more than double the 2-year survival compared to chemo! Remission rates were also much higher. There’s a catch—more risk of liver complications—so docs need to keep an eye out. Still, this could be a real game-changer for ALL patients! #LeukemiaResearch #ALL #CancerTreatment #MedicalBreakthrough #StemCellTransplant #Health